FDA approved BristolMeyers – Astrazeneca’s Farxiga to treat type 2 diabetes
The U.S. Food and Drug Administration approved Farxiga (dapaglifozin) tablets to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes. Type 2 diabetes affects about 24 million people and accounts for more than 90 percent of diabetes cases diagnosed